mineralocorticoid receptor antagonist + SGLT-2 inhibitor

This refers to the combination therapy of a mineralocorticoid receptor antagonist (MRA) and a sodium-glucose cotransporter 2 inhibitor (SGLT-2i). MRAs, such as spironolactone, eplerenone, or finerenone, block the action of aldosterone at the mineralocorticoid receptor, reducing sodium retention and fibrosis in cardiovascular and renal tissues. SGLT-2 inhibitors (e.g., dapagliflozin, empagliflozin) reduce glucose reabsorption in the proximal renal tubule, leading to glycosuria and natriuresis. The combination targets non-overlapping pathways—MRAs act on hormonal regulation while SGLT-2 inhibitors affect metabolic and hemodynamic processes—providing additive benefits for patients with chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF), and albuminuria. Clinical studies show that this combination reduces albuminuria more than either agent alone[1][3][5], lowers blood pressure[1], may reduce risk of hyperkalemia compared to MRA monotherapy[9], and offers potential additive protection against cardiovascular events[4]. Both drug classes are small molecules.